JP7555155B2 - 新規ｐｌｋ１分解誘導化合物 - Google Patents

新規ｐｌｋ１分解誘導化合物 Download PDF

Info

Publication number
JP7555155B2
JP7555155B2 JP2023514149A JP2023514149A JP7555155B2 JP 7555155 B2 JP7555155 B2 JP 7555155B2 JP 2023514149 A JP2023514149 A JP 2023514149A JP 2023514149 A JP2023514149 A JP 2023514149A JP 7555155 B2 JP7555155 B2 JP 7555155B2
Authority
JP
Japan
Prior art keywords
methyl
mmol
amino
cancer
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023514149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540728A (ja
Inventor
リュ，スーヒー
ミン，インスク
リ，ハンキョ
キム，ソンフン
リュ，ヒェグク
カン，クムヤン
キム，サンヨン
チュン，ソヒョン
リ，ジョンキョ
リ，ギッブム
Original Assignee
オップテラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オップテラ インコーポレイテッド filed Critical オップテラ インコーポレイテッド
Publication of JP2023540728A publication Critical patent/JP2023540728A/ja
Application granted granted Critical
Publication of JP7555155B2 publication Critical patent/JP7555155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023514149A 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物 Active JP7555155B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
KR20210105358 2021-08-10
KR10-2021-0105358 2021-08-10
KR10-2021-0106488 2021-08-12
KR20210106488 2021-08-12
KR10-2021-0117389 2021-09-03
KR20210117389 2021-09-03
KR10-2021-0126757 2021-09-24
KR20210126757 2021-09-24
KR20220008456 2022-01-20
KR10-2022-0008456 2022-01-20
KR20220020996 2022-02-17
KR10-2022-0020996 2022-02-17
KR20220054880 2022-05-03
KR10-2022-0054880 2022-05-03
KR20220075838 2022-06-21
KR10-2022-0075838 2022-06-21
PCT/KR2022/011961 WO2023018236A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound

Publications (2)

Publication Number Publication Date
JP2023540728A JP2023540728A (ja) 2023-09-26
JP7555155B2 true JP7555155B2 (ja) 2024-09-24

Family

ID=85200656

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507883A Pending JP2024530495A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507883A Pending JP2024530495A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Country Status (15)

Country Link
US (4) US11939334B2 (enExample)
EP (4) EP4157850A4 (enExample)
JP (4) JP7555155B2 (enExample)
KR (5) KR102604802B1 (enExample)
CN (2) CN116261458B (enExample)
AU (1) AU2022327025A1 (enExample)
CA (1) CA3228601A1 (enExample)
CL (1) CL2024000373A1 (enExample)
CO (1) CO2024001256A2 (enExample)
CR (1) CR20240120A (enExample)
EC (1) ECSP24010109A (enExample)
IL (1) IL310678A (enExample)
MX (1) MX2024001774A (enExample)
PE (1) PE20240894A1 (enExample)
WO (5) WO2023017446A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530757A (ja) * 2023-02-02 2025-09-17 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
CN118946561A (zh) * 2023-03-10 2024-11-12 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
TW202502750A (zh) 2023-06-08 2025-01-16 美商新銳思生物製藥股份有限公司 Smarca2之雙官能選擇性降解劑及其治療用途
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途
EP4780815A1 (en) 2023-09-20 2026-07-29 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
US20250197411A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN118724841B (zh) * 2024-06-14 2026-06-19 南通华祥医药科技有限公司 一种n-氨基哌啶二盐酸盐的制备方法
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026041138A1 (zh) * 2024-08-22 2026-02-26 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途
WO2026114368A1 (zh) * 2024-11-28 2026-06-04 西藏海思科制药有限公司 一种vav1靶向降解剂及其用途
WO2026114367A1 (zh) * 2024-11-28 2026-06-04 西藏海思科制药有限公司 Vav1靶向降解剂及其用途
WO2026114343A1 (zh) * 2024-11-29 2026-06-04 上海美悦生物科技发展有限公司 杂环化合物、及其药物组合物和用途
WO2026158584A1 (zh) * 2025-01-25 2026-07-30 杭州和正医药有限公司 多杂环类vav1降解分子衍生物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542613A (ja) 2006-07-06 2009-12-03 アストラゼネカ アクチボラグ 新規化合物
JP2010521514A (ja) 2007-03-22 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
CN106543185A (zh) 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN109879877A (zh) 2019-03-04 2019-06-14 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021053495A1 (en) 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
WO2021061894A1 (en) 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010542B1 (en) * 2006-04-12 2012-01-25 Vertex Pharmaceuticals Incorporated 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridines as plk1 protein kinase inhibitors for the treatment of proliferative disorders
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN106977584B (zh) * 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542613A (ja) 2006-07-06 2009-12-03 アストラゼネカ アクチボラグ 新規化合物
JP2010521514A (ja) 2007-03-22 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
CN106543185A (zh) 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN109879877A (zh) 2019-03-04 2019-06-14 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021053495A1 (en) 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
WO2021061894A1 (en) 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530757A (ja) * 2023-02-02 2025-09-17 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Also Published As

Publication number Publication date
JP2023540728A (ja) 2023-09-26
CN116322700B (zh) 2024-08-20
KR102604801B1 (ko) 2023-11-22
WO2023018237A1 (en) 2023-02-16
EP4157849A1 (en) 2023-04-05
EP4384521A4 (en) 2025-09-03
ECSP24010109A (es) 2024-05-31
KR20230024251A (ko) 2023-02-20
IL310678A (en) 2024-04-01
MX2024001774A (es) 2024-04-24
US20250114460A1 (en) 2025-04-10
KR20230024302A (ko) 2023-02-20
KR20230024250A (ko) 2023-02-20
KR20240060721A (ko) 2024-05-08
US11939334B2 (en) 2024-03-26
KR102604803B1 (ko) 2023-11-22
AU2022327025A1 (en) 2024-03-21
WO2023018238A1 (en) 2023-02-16
CO2024001256A2 (es) 2024-03-18
EP4384520A4 (en) 2025-09-03
EP4157850A4 (en) 2024-11-20
US20230219966A1 (en) 2023-07-13
CA3228601A1 (en) 2023-02-16
EP4384521A1 (en) 2024-06-19
EP4157850A1 (en) 2023-04-05
KR102662205B1 (ko) 2024-04-30
JP2024530195A (ja) 2024-08-16
PE20240894A1 (es) 2024-04-24
KR20230024267A (ko) 2023-02-20
US20250101025A1 (en) 2025-03-27
US20230242541A1 (en) 2023-08-03
CR20240120A (es) 2024-05-22
EP4157849A4 (en) 2024-12-11
WO2023017442A1 (en) 2023-02-16
KR102604802B1 (ko) 2023-11-22
CN116261458B (zh) 2024-05-24
WO2023018236A1 (en) 2023-02-16
JP2024530495A (ja) 2024-08-21
EP4384520A1 (en) 2024-06-19
CN116261458A (zh) 2023-06-13
WO2023017446A1 (en) 2023-02-16
CL2024000373A1 (es) 2024-07-19
CN116322700A (zh) 2023-06-23
JP7555156B2 (ja) 2024-09-24
JP2023540729A (ja) 2023-09-26
US11912710B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
KR102604801B1 (ko) 신규 plk1 분해 유도 화합물
CN109641899A (zh) 作为内体Toll样受体抑制剂的化合物及组合物
HK1203507A1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
US12534457B2 (en) Heteroaryl derivative compounds, and uses thereof
TW202330532A (zh) Ｔｒｐｍｌ之調節劑、其組合物及使用方法
AU2023330130A1 (en) Compounds and methods for modulating her2
EP2875025A1 (en) Fused triazole derivatives as gamma secretase modulators
KR20250105638A (ko) 경직성이 증가된 plk1 분해 유도 화합물
CN117794936A (zh) 新型plk1降解诱导化合物
JP2026509069A (ja) ２，４－ジアニリノピリミジンベースのオーロラａキナーゼ選択的分解誘導化合物
JP2025530757A (ja) 新規ｐｌｋ１分解誘導化合物
TWI772370B (zh) 作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
EA052736B1 (ru) Гетероарильные производные и их применение
HK40006173B (en) Fused quadracyclic compounds, compositions and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240903

R150 Certificate of patent or registration of utility model

Ref document number: 7555155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150